Persistent neurotoxicity of systemically administered interferon‐alpha
The DOI matches its Crossref record.
Abstract
Fourteen cancer patients had evidence of persistent neurotoxicity of interferon-alpha therapy long after their treatment was discontinued. Although most of the cognitive symptoms were mild to moderate in severity, they were incapacitating to these individuals in their usual work. The neuropsychological test abnormalities were not attributable to subsequent therapy, disease status, or other medical problems. The pattern of deficits was consistent with frontal-subcortical dysfunction. Of the four patients who had follow-up assessment, two had improved and two had deteriorated. These findings suggest that in some cases interferon neurotoxicity is not reversible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797
Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer
Miller, A. H., Ancoli-Israel, S., Bower, J. E., Capuron, L., & Irwin, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7805 · Cited by 608
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy
Barlow, C. F., Priebe, C. J., Mulliken, J. B., Barnes, P. D., Mac Donald, D., Folkman, J., & Ezekowitz, R. A. B. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70034-4 · Cited by 441
Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
Dieperink, E., Willenbring, M., & Ho, S. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.867 · Cited by 422
Cancer-treatment-induced neurotoxicity—focus on newer treatments
Stone, J. B., & DeAngelis, L. M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.152 · Cited by 274
Clinical Toxicity of the Interferons
Vial, T., & Descotes, J. (1994) · Drug Safety · doi:10.2165/00002018-199410020-00003 · Cited by 269
Role of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257
“It is well established that ~ 30 – 45% of patients receiving IFN treatment develop depressive-like symptoms during the course of therapy, with a proportion of them experiencing these symptoms long after therapy has ceased (Meyers et al , 1991; Miyaoka et al , 1999).”
Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α
PEMBERTON, L. A., KERR, S. J., SMYTHE, G., & BREW, B. J. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.589 · Cited by 149
Majer, M., Welberg, L. A. M., Capuron, L., Pagnoni, G., Raison, C. L., & Miller, A. H. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.12.009 · Cited by 124
Neuropsychiatric disorders related to interferon and interleukins treatment
Myint, A. M., Schwarz, M. J., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9114-5 · Cited by 116
Mood and cognitive disorders in cancer patients receiving cytokine therapy.
Meyers, C. A. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_5 · Cited by 98
Self-citationLieb, K., Engelbrecht, M. A., Gut, O., Fiebich, B. L., Bauer, J., Janssen, G., & Schaefer, M. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.030 · Cited by 77
Fahey, B., Hickey, B., Kelleher, D., O’Dwyer, A.-M., & O’Mara, S. M. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.05.005 · Cited by 43
Effect of Interferon-α on cognitive functioning in patients with chronic hepatitis C
HILSABECK, R. C., HASSANEIN, T. I., ZIEGLER, E. A., CARLSON, M. D., & PERRY, W. (2005) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617705050022 · Cited by 40
“…slowing of frontal lobe waveforms in patients receiving high doses of IFN-a (Rohatiner et al., 1983; Smedley et al., 1983; Suter et al., 1984) and by a pattern of neuropsychological deficits of patients undergoing IFN-a therapy (Meyers et al., 1991b; Pavol et al., 1995; Valentine et al., 1998).”
BackgroundResultInfluentialFontana, R. J., Bieliauskas, L. A., Lindsay, K. L., Back‐Madruga, C., Wright, E. C., Snow, K. K., Lok, A. S. F., Kronfol, Z., & Padmanabhan, L. (2007) · Hepatology · doi:10.1002/hep.21633 · Cited by 38
Makino, M., Kitano, Y., Komiyama, C., Hirohashi, M., & Takasuna, K. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703432 · Cited by 38
Recovery after l-DOPA treatment in peginterferon and ribavirin induced parkinsonism
Bersano, A., Aghemo, A., Rumi, M. G., Ballabio, E., Candelise, L., & Colombo, M. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.10.003 · Cited by 26
Caraceni (1998) · doi:10.1002/(sici)1097-0142(19980801)83:3
Metadata
- Authors
- Meyers, C. A., Scheibel, R. S., & Forman, A. D.
- Venue
- Neurology
- Published
- 1991-05
- Volume
- 41
- Issue
- 5
- Pages
- 672-676
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2093896551
- Cited by
- 208
- References
- 0
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.